RecruitingPhase 3NCT05609630
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Studying Juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Upadacitinib(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- Phoenix Children's Hospital /ID# 253403, Phoenix, Arizona, United States
- Childrens National Medical Center /ID# 253344, Washington D.C., District of Columbia, United States
- New York Medical College /ID# 253437, Valhalla, New York, United States
- Levine Children's Hospital /ID# 253491, Charlotte, North Carolina, United States
- Cincinnati Childrens Hospital Medical Center /ID# 251827, Cincinnati, Ohio, United States
- Randall Children's Hospital /ID# 251829, Portland, Oregon, United States
- Instituto CAICI S.R.L /ID# 251448, Rosario, Santa Fe Province, Argentina
- Centro de Investigaciones Medicas Tucuman /ID# 251781, San Miguel de Tucumán, Tucumán Province, Argentina
- Hospital de Niños de la Santisima Trinidad /ID# 252736, Córdoba, Argentina
- Monash Health - Monash Medical Centre /ID# 251691, Clayton, Victoria, Australia
- Royal Children's Hospital /ID# 251663, Parkville, Victoria, Australia
- Landeskrankenhaus Bregenz /ID# 266317, Bregenz, Vorarlberg, Austria
- CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 251769, Juiz de Fora, Minas Gerais, Brazil
- Hospital Sao Paulo /ID# 251765, São Paulo, Brazil
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 251764, São Paulo, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05609630 on ClinicalTrials.govOther trials for Juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT07386587Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic ArthritisUniversity of Child Health Sciences and Children's Hospital, Lahore
- RECRUITINGPHASE3NCT06654882Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisDuke University
- RECRUITINGNCT07243782Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in KoreaNovartis Pharmaceuticals
- RECRUITINGNANCT07217782Pain in Juvenile ArthritisWashington University School of Medicine
- RECRUITINGNCT07185750Investigation of Catastrophizing of Pain Reported by Parents in JIA PatientsHacettepe University
- RECRUITINGNANCT07234747Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic ArthritisIstanbul University - Cerrahpasa
- RECRUITINGNCT06806774Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopathic ArthritisHacettepe University
- RECRUITINGNANCT06474546Feasibility of a Diet Intervention for Juvenile ArthritisThe Hospital for Sick Children